Table 1 Patients characteristics in the poor and better prognostic group

Postoperative survival months

Mean ± SD^a

21.0 ± 4.80

58.1 ± 13.0

0.0067^b

Age

Mean ± SD

66.75 ± 10.66

63.25 ± 12.95

0.6909^c

Gender

Male

3(75)

3(75)

Female

1(25)

1(25)

Location

Head

4(100)

4(100)

T

T3

4(100)

4(100)

N

N1

4(100)

4(100)

M

M0

4(100)

4(100)

UICC stage

IIB

4(100)

4(100)

JPS stage

3

4(100)

4(100)

Differentiation

Moderate

4(100)

4(100)

Residuum

R0

4(100)

4(100)

Postoperative CA19-9

<37 U/ml

4(100)

4(100)

Adjuvant chemotherapy

Gemcitabine

4(100)

4(100)